ArticleClinical and translational science2022

Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor.

Yan Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.